Answers are grounded in this paper and cite their sources.
Observational analysis reveals significant radiological and serological responses to olaparib in metastatic castration-resistant prostate cancer, indicating potential for targeted therapy.
In metastatic CRPC harboring a BRCA2 mutation and near-threshold TMB, olaparib produced clear radiological and serological responses.
No takes yet. Share an insight, caveat, or question.
Yokota et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: